HALIX Launches HALiXPEDITE Platform for Streamlined Biologics Manufacturing

• HALIX has launched its HALiXPEDITE platform at the Innovation for Health conference in Rotterdam to accelerate biologics development.

• The platform aims to streamline the transition from late-stage R&D to GMP manufacturing, enabling a faster First-in-Human (FiH) pathway.

HALIX, a global healthcare Contract Development and Manufacturing Organization (CDMO), has introduced HALiXPEDITE, a new platform designed to fast-track biologics-based therapies to First-in-Human (FiH) trials. The platform was officially unveiled at the Innovation for Health conference in Rotterdam.

The new platform addresses long-standing challenges in biologics development, including high costs, production bottlenecks, and a disconnect between research and GMP manufacturing. HALiXPEDITE integrates cell line development through to GMP production, aiming to reduce delays and financial risks associated with early-phase clinical progression.

According to HALIX, the initiative also includes access to a BioHub that connects therapy developers with broader expertise in Intellectual Property, AI and Machine Learning, and Chemistry, Manufacturing and Control (CMC) management. All support services are coordinated through a single point of contact.

“Our mission with HALiXPEDITE is to redefine the landscape of biologics therapy development by providing early process integration and fostering a wide net of expert collaboration,” said Dr. Lutz Hilbrich, CEO of HALIX.

The CDMO intends HALiXPEDITE to be a solution for biopharma companies aiming to move their therapies forward without the delays often associated with infrastructure access and fragmented service providers.